Drug intelligence / Profile preview

EcoVag

Development stage: Phase 4
Lead developer: Bifodan
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Vaginal

Overview

EcoVag is a probiotic vaginal capsule formulation composed of two specific strains of lactic acid-producing bacteria: *Lactobacillus gasseri* DSM 14869 and *Lactobacillus rhamnosus* DSM 14870. Originally isolated from the vaginal epithelial cells of healthy women, these strains were selected for their high adhesive capacity and ability to maintain a healthy vaginal microbiota. The mechanism involves the colonization of the vaginal mucosa, acidification of the environment to a low pH (approximately 3.8), and the production of antimicrobial factors such as hydrogen peroxide and bacteriocins. EcoVag is primarily used as an adjunct to standard antibiotic or antifungal treatments to provide a long-term cure and reduce the rate of relapse in women with bacterial vaginosis (BV) and recurrent vulvovaginal candidiasis (VVC).

Brand names: EcoVag
Other names: EcoVag probiotic vaginal capsules

Beyond the preview

Go deeper on EcoVag.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EcoVag.

Explore the full profile